The p53 tumor suppresser gene is often mutated in various human cancers and a common polymorphism is known at codon 72 of exon 4, with two alleles encoding either arginine (CGC) or proline (CCC). Association of this polymorphism with any human cancer susceptibility has yet to be clarified. We have conducted a case-control study in Japan on the distribution of the three genotypes with 191 lung cancer patients, 152 control patients with noncancerous pulmonary diseases and 115 colorectal cancer patients. The genotypes were examined by PCR using DNA samples from peripheral blood lymphocytes. Frequency distributions of the three genotypes were quite comparable with each other among groups, with allelic frequencies of -60% for arginine and 40% for proline. The genotypic frequencies in lung cancer patients, however, were largely different between smokers and non-smokers (% 2 = 13.5, df = 2, P < 0.001). Compared with the control and colorectal cancer patients a significant difference in genotypic frequency was observed only in non-smoker lung cancers (x 2 = 10.9, df = 2, P < 0.01), with an excess of Arg/Arg homozygotes and a deficit of Arg/Pro heterozygotes. Our present data suggest that the p53 polymorphism affects the risk of lung cancer unrelated to smoking.
Introduction
Lung carcinogenesis in humans requires exposure to environmental noxious agents, mainly tobacco smoke, and a genetic susceptibility that could reflect individual's metabolism of carcinogens (1,2). To date variations in lung cancer susceptibility have been evaluated with regard to genetic polymorphisms of cytochrome P-450 enzymes (e.g. CYP1A1) and GST1 enzymes (3), both of which are involved in the metabolism of carcinogens contained in tobacco smoke. It is also possible that polymorphisms of other genes contribute to a genetic predisposition to lung cancer.
The p53 tumor suppresser gene is frequently mutated in many forms of human carcinomas, including lung cancer. Although the molecular mechanisms of p53 protein function remain to be fully characterized, there are ample data which indicate its important role in carcinogenesis (4) . Germ line mutations of this gene, which predispose to a variety of human cancers, including Li-Fraumeni syndrome, have also been reported (5) . There is a common polymorphic site in the wildtype gene located at codon 72 of exon 4, with two alleles encoding either arginine (CGC) or proline (CCC) (6) .
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Association of p53 polymorphism with lung cancer susceptibility has been studied by several authors (7-9). Weston et al. found an increased frequency of the proline allele only in adenocarcinomas (7), but later they could not confirm this finding with a different set of cases and controls (8) . The combined data of both their studies indicate no significant difference in genotypic frequencies between the cases and controls. Kawajiri et al. demonstrated , by testing a large number of patients with cancers of various organs and healthy controls, a significant increase in proline homozygotes in the lung cancer group, especially in Kreyberg type I, a group of histological types strongly associated with smoking, but not in adenocarcinoma (9) .
Thus the results reported were not consistent with respect to the association of codon 72 polymorphism with lung cancer susceptibility. In the present study we conducted a case-control study to further investigate the genotypic frequency at codon 72 in lung cancer patients with reference to their tobacco smoking histories.
Materials and methods
The cases were 191 lung cancer patients who were admitted to either the Chiba Cancer Center Hospital or the Chiba University Hospital between 1991 and 1995. For controls 152 patients with non-cancerous pulmonary diseases were chosen from the out-patients of the former hospital. In addition, 115 colorectal cancer patients admitted to the Chiba Cancer Center Hospital were also submitted for the genotype test. They were enrolled as a second control group, because tobacco smoking is not ecologically associated with colorectal cancer (10) and also because a previous report could not detect any positive association of p53 polymorphism with this cancer (9) . Information on the smoking history of these study subjects was obtained from the hospital records. They were classified into smoking and non-smoking groups, the former including both current smokers and ex-smokers. We did not further divide the smokers into subgroups of different smoking grades, because of the few subjects for test. As to the prognosis of the lung cancer patients, long-term follow-up could not be carried out in all cases. We examined the short-term prognosis within 2 years after their discharge.
DNA samples were extracted from peripheral blood lymphocytes with a DNA extraction kit (WB kit; Wako Pure Chemicals, Tokyo, Japan). Genotyping of the p53 gene at codon 72 was carried out by the PCR method, with two 5' primers, either 5'-ATGCCAGAGGCTGCTCCCCG-3' or 5'-ATGCCA-GAGGCTGCTCCCCC-3' (corresponding to Arg and Pro encoding alleles respectively), and 3' primer 5'-GCAACTGACCGTGCAAGTCA-3' for the other strand (9) . Amplification was for 30 cycles under the following conditions: 1 min at 95°C for denaturation, 1 min at 60°C for primer annealing and 1 min at 72°C for primer extension with Ampli Taq DNA polymerase (Perkin-Elmer Cetus, Norwalk, CT). The PCR products were subjected to electrophoresis in 2% agarose gels (Wako Pure Chemicals). The 189 bp band was detected by allele-specific priming ( Figure 1A ).
The polymorphism was confirmed by Accll restriction enzyme digestion, which discriminates between the polymorphic sites. The PCR-amplified DNA prepared with the 5' primer 5'-ATCTACAGTCCCCCTTGCCG-3' and the above 3' primer was digested with Acctt (Takara Shuzo, Otsu, Japan) for 90 min at 37°C and the products subjected to electrophoresis in 2% agarose gels. Since the Arg encoding allele fragment, but not the Pro encoding allele fragment has a single Accll recognition site (CGCG) (11,12), the former fragment was determined as two bands of 169 and 127 bp and the latter as a single band of 296 bp ( Figure 1B ).
The Pearson x 2 test OT Fisher's exact probability test was used to compare the frequency distribution of p53 genotypes between different study groups. The Hardy-Weinberg equilibrium of genotypic frequencies was tested by a R P R P R P Ace II -+ -+ -+ 
Results
In Table I the results of p53 genotyping of the three groups are shown, i.e. lung cancer patients, controls and colorectal cancer patients. The frequencies of the three genotypes, Arg/ Arg, Arg/Pro and Pro/Pro, were 34.9, 50.0 and 15.1% respectively in the controls. Based on these data the frequency of the Arg encoding allele is estimated to be 60% and that of the Pro encoding allele 40%. The distribution of the three genotypes fitted well to the Hardy-Weinberg equilibrium. No significant difference was observed between sexes (data not shown). The genotypic frequencies in the lung cancer patients as well as in the colorectal cancer patients were both quite similar to that of the controls. Thus this polymorphism of the p53 gene is not associated with a susceptibility to cancer in general. "Prognosis within 2 years after discharge. b The smoking group includes both current smokers and ex-smokers. The difference between the smoking and non-smoking groups is statistically significant (x 2 = 13.5, df = 2, P < 0.001). •Genotypic frequencies in lung cancer patients are significantly different either from those in controls (y} = 9.4, df = 2, P < 0.01) and from those of controls and colorectal cancer patients combined (x 2 = 10.9, df = 2,
The lung cancer patients were classified by gender, age class, prognosis, the histological type of tumor and smoking habit (Table II) . The genotypic frequencies were slightly different by gender and by the histological type of tumor, but these were not statistically significant. These differences should be ascribed to the patients' smoking history (see Discussion). No significant difference was observed between the younger (<60) and older (>60) age classes of lung cancer patients. Regarding the prognosis of patients, the number of Pro/Pro homozygotes seemed to be small in deceased cases. This, however, was not statistically significant by Fisher's exact probability test compared with the numbers of the other genotypes (P = 0.12).
With respect to smoking habit the genotypic frequencies were significantly different between smokers (including exsmokers) and non-smokers (x 2 = 13.5, df = 2, P < 0.001). This was primarily due to the relative proportions of the Arg/ Arg homozygote with respect to the Arg/Pro heterozygote. Arg/Arg homozygotes were more and Arg/Pro heterozygotes were less frequent in lung cancer patients who didn't smoke than in those who smoked, whereas the frequency of Pro/Pro homozygotes was largely constant between the two groups. This difference regarding smoking habit is unique to lung cancer patients, because it was not observed either in the controls or in the colorectal cancer patients (Table III) . The lung cancer patients who did not smoke comprised a significantly larger proportion of Arg/Arg homozygotes and a smaller proportion of Arg/Pro heterozygotes compared with the controls (x 2 = 9.4, df = 2, P < 0.01) or with controls and colorectal cancer patients inclusively (x 2 = 10.9, df = 2, P < 0.01). On the other hand, in the lung cancer patients who smoked heterozygotes were more predominant than in the controls, but without statistical significance (% 2 = 1.3, df = 2, 0.5 < P < 0.6).
Discussion
The number of subjects enrolled for the present study is relatively small, but the obtained frequencies of p53 genotypes are reliable, because they were fitted to the Hardy-Weinberg equilibrium in any one of the three groups. The frequencies in the control group are also comparable with a previous report on more than 300 healthy Japanese controls (9) . According to the studies of Weston et al. there should be a racial difference in the frequency of the p53 polymorphism between AfricanAmericans and Caucasians in the USA (7, 8) . The gene frequencies in the Japanese population obtained by us and also by Kawajiri et al. (9) are in accord with that of the Caucasian population. Concerning colorectal cancer, we and Kawajiri et al. (9) agree that the p53 polymorphism is not related to the incidence of colorectal cancer. Another study on Caucasian subjects showed no association of Pro/Pro homozygotes with colorectal cancer either (14) .
A notable result with respect to lung cancer susceptibility was that Arg/Arg homozygotes were frequent and Arg/Pro heterozygotes were few in number among the patients who smoked. Thus Arg/Arg homozygotes seem to be susceptible to smoking-unrelated lung cancer or, alternatively, Arg/Pro heterozygotes are resistant to it. Weston et al. initially reported that the Pro encoding allele was more predominant in adenocarcinoma patients than in the other histological types (7). However, their later study disproved this finding (8) . Kawajiri et al. demonstrated an increased frequency of the Pro/Pro homozygote in Kreyberg type I lung cancer, which is strongly associated with smoking, but not in Kreyberg type II (adenocarcinoma) (9) . Our data reveal that the Pro/Pro homozygote frequency does not increase in lung cancer patients, irrespective of histological type.
A recent report by Jin et al. showed a positive association of Pro/Pro homozygotes with lung cancer, as did Kawajiri et al., but this observation was restricted to younger patients (<53 years) and light smokers (<30 pack-years) (15) . Our study did not show any differences in genotypic frequency by age class (Table II) . We also examined the possible effect of smoking dose on an association of the p53 polymorphism with lung cancer susceptibility. However, the frequency of Pro/ Pro homozygotes among the lung cancer patients was not significantly different from the control and colorectal cancer patients, both in light smokers (<40 pack-years; f} = 0.01, df = 1, 0.90 < P < 0.95) and in heavier smokers (2=40 packyears; x 2 = 1.0, df = 1, 0.3 < P < 0.4). Thus our result does not agree with the findings of Jin et al.
Bergander et al. tested not only the codon 72 polymorphism but also two other sites in the p53 gene, i.e. the Mspl restriction site in intron 6 and the 16 bp duplication in intron 3 (16) . While a positive association of the codon 72 polymorphism was not observed, they demonstrated a significant increase in haplotype of the Pro encoding allele and 16 bp Al allele (no duplication) in lung cancer patients compared with patients with chronic obstructive pulmonary disease. They also found that the same haplotype was associated with colorectal cancer and implied a linkage disequilibrium with a certain mutation in the p53 gene, which is hitherto undetected, but functionally important (14) . We cannot perform a similar haplotype analysis with the present study population, since the polymorphism in intron 3 is so rare in the Japanese population (17) . Our results present a different association of the p53 polymorphism with lung cancer from previous reports (7) (8) (9) 15, 16) . Smoking-unrelated lung cancer was more prevalent among Arg/Arg homozygotes and less among Arg/Pro heterozygotes. This preferential polymorphism was not observed in smoking-related lung cancer. Since factors other than tobacco smoke are not known to contribute to lung cancer incidence (18) , analysis of susceptibility to smoking-unrelated lung cancer is hampered at present. Additional information about patient's occupations, life-styles and living environments were also available, but we could find no specific factors which suggest a causative relation with smoking-unrelated lung cancer. Further investigation is required to obtain information on etiological agents, including environmental tobacco smoke, to clarify a possible role of the p53 polymorphism in smokingunrelated lung carcinogenesis.
